PL3789038T3 - Humanizowane i chimeryczne przeciwciała monoklonalne wobec cd47 - Google Patents

Humanizowane i chimeryczne przeciwciała monoklonalne wobec cd47

Info

Publication number
PL3789038T3
PL3789038T3 PL20198499.4T PL20198499T PL3789038T3 PL 3789038 T3 PL3789038 T3 PL 3789038T3 PL 20198499 T PL20198499 T PL 20198499T PL 3789038 T3 PL3789038 T3 PL 3789038T3
Authority
PL
Poland
Prior art keywords
humanized
monoclonal antibodies
chimeric monoclonal
chimeric
antibodies
Prior art date
Application number
PL20198499.4T
Other languages
English (en)
Inventor
Jie Liu
Irving L. Weissman
Ravindra Majeti
Original Assignee
The Board Of Trustees Of The Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Board Of Trustees Of The Leland Stanford Junior University filed Critical The Board Of Trustees Of The Leland Stanford Junior University
Publication of PL3789038T3 publication Critical patent/PL3789038T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PL20198499.4T 2010-05-14 2011-05-13 Humanizowane i chimeryczne przeciwciała monoklonalne wobec cd47 PL3789038T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39565210P 2010-05-14 2010-05-14

Publications (1)

Publication Number Publication Date
PL3789038T3 true PL3789038T3 (pl) 2023-01-23

Family

ID=44915009

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20198499.4T PL3789038T3 (pl) 2010-05-14 2011-05-13 Humanizowane i chimeryczne przeciwciała monoklonalne wobec cd47

Country Status (13)

Country Link
US (6) US9017675B2 (pl)
EP (4) EP2569013B1 (pl)
JP (6) JP6166177B2 (pl)
AU (5) AU2011252851B2 (pl)
CA (2) CA2797720C (pl)
DK (2) DK3789038T3 (pl)
ES (2) ES2937174T3 (pl)
HR (2) HRP20221260T1 (pl)
HU (2) HUE060541T2 (pl)
LT (1) LT3789038T (pl)
PL (1) PL3789038T3 (pl)
PT (2) PT2569013T (pl)
WO (1) WO2011143624A2 (pl)

Families Citing this family (179)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2711370C (en) 2008-01-15 2017-06-13 The Board Of Trustees Of The Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
US11072655B2 (en) 2008-01-15 2021-07-27 The Board Of Trustees Of The Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
PT3056515T (pt) * 2008-01-15 2019-07-19 Univ Leland Stanford Junior Métodos para manipulação da fagocitose mediada por cd47
DK2429574T3 (da) 2009-05-15 2015-06-22 Univ Health Network Sammensætninger og fremgangsmåder til behandling af hæmatologiske cancere der targeterer sirp-cd47-interaktionen
AU2011252851B2 (en) * 2010-05-14 2016-10-06 The Board Of Trustees Of The Leland Stanford Junior University Humanized and chimeric monoclonal antibodies to CD47
US9873918B2 (en) 2011-08-11 2018-01-23 Albert Einstein College Of Medicine, Inc. Treatment of acute myeloid leukemia and myelodysplastic syndromes
ME03512B (me) 2012-02-06 2020-04-20 Inhibrx Inc Cd47 antitijela i postupci za njihovu upotrebu
RU2693078C2 (ru) 2012-12-03 2019-07-01 Новиммун С.А. Анти-cd47 антитела и способы их применения
MX2015007446A (es) * 2012-12-12 2015-12-07 Vasculox Inc Anticuerpos terapeuticos para cd47.
US9221908B2 (en) 2012-12-12 2015-12-29 Vasculox, Inc. Therapeutic CD47 antibodies
ME03550B (me) 2012-12-17 2020-07-20 Trillium Therapeutics Inc Lečenje cd47+ obolelih ćelija sa sirp alfa-fc fuzijama
WO2014121093A1 (en) 2013-01-31 2014-08-07 Thomas Jefferson University Fusion proteins that facilitate cancer cell destruction
EP3311824B1 (en) 2013-02-05 2020-03-25 The Board of Trustees of the Leland Stanford Junior University Cd47 targeted therapies for the treatment of infectious disease
SG10201706383XA (en) * 2013-02-06 2017-09-28 Inhibrx Lp Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
CA2905418C (en) 2013-03-13 2023-03-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for modulating chemotherapeutic cytotoxicity
CN105189556A (zh) 2013-03-15 2015-12-23 小利兰·斯坦福大学托管委员会 用于实现治疗有效剂量的抗cd47剂的方法
WO2014179132A1 (en) 2013-04-29 2014-11-06 The Board Of Trustees Of The Leland Stanford Junior University Use of anti-cd47 agents to enhance immunization
SG11201601823TA (en) 2013-09-13 2016-04-28 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
PL3044323T3 (pl) 2013-09-13 2022-06-27 F.Hoffmann-La Roche Ag Sposoby wykrywania i ilościowego oznaczania białka komórki gospodarza w liniach komórkowych
ES2765483T3 (es) * 2013-09-18 2020-06-09 Univ Leland Stanford Junior Modulación de las vías de eferocitosis para el tratamiento de una enfermedad aterosclerótica
US11046763B2 (en) 2014-01-08 2021-06-29 The Board Of Trustees Of The Leland Stanford Junior University Targeted therapy for small cell lung cancer
ES2811274T3 (es) 2014-04-18 2021-03-11 Univ Leland Stanford Junior Anticuerpos monoclonales humanizados y quiméricos para CD99
ES2751915T5 (es) 2014-08-15 2022-12-23 Merck Patent Gmbh Proteínas de fusión de inmunoglobulina con SIRP alfa
ES2945588T3 (es) 2014-08-26 2023-07-04 Univ Leland Stanford Junior Injerto de células madre con una combinación de un agente dirigido a las células madre y modulación de señalización inmunoreguladora
US10822411B2 (en) * 2014-09-15 2020-11-03 The Board Of Trustees Of The Leland Stanford Junior University Targeting aneurysm disease by modulating phagocytosis pathways
AU2015329696A1 (en) 2014-10-10 2017-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods to eliminate cancer stem cells by targeting CD47
WO2016065329A1 (en) 2014-10-24 2016-04-28 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for inducing phagocytosis of mhc class i positive cells and countering anti-cd47/sirpa resistance
WO2016081423A1 (en) * 2014-11-18 2016-05-26 Janssen Pharmaceutica Nv Cd47 antibodies, methods, and uses
EP3247464B1 (en) 2015-01-21 2019-09-18 The Board of Trustees of the Leland Stanford Junior University Use of tlr agonist and anti-cd47 agent to enhance phagocytosis of cancer cells
ES2838925T3 (es) 2015-02-27 2021-07-02 Univ Leland Stanford Junior Terapia de combinación para el tratamiento de la ateroesclerosis
AR103868A1 (es) * 2015-03-04 2017-06-07 Sorrento Therapeutics Inc Anticuerpos anti-cd47 como agentes terapéuticos
DK3277725T3 (da) 2015-03-30 2021-01-11 Regeneron Pharma Konstante tungkædeområder med reduceret binding til FC-gammareceptorer
RU2740672C2 (ru) 2015-08-07 2021-01-19 ЭйЭлЭкс Онколоджи Инк. Конструкции, имеющие sirp-альфа домен или его вариант
ES2894335T5 (es) 2015-08-26 2024-06-27 Univ Leland Stanford Junior Reducción mejorada de células objetivo con bloqueo de CD47 y un agonista coestimulador inmune
CN116425875A (zh) 2015-09-18 2023-07-14 安驰肿瘤公司 治疗性cd47抗体
US9650441B2 (en) 2015-09-21 2017-05-16 Erasmus University Medical Center Anti-CD47 antibodies and methods of use
PT3370768T (pt) * 2015-11-03 2022-04-21 Janssen Biotech Inc Anticorpos que se ligam especificamente ao pd-1 e seus usos
JP6976960B2 (ja) 2015-11-27 2021-12-08 カーサリクス プロプライエタリー リミテッド 遺伝子改変された細胞およびその使用
KR102988978B1 (ko) 2015-12-11 2026-07-10 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 Cd47 및 egfr의 이중 표적화를 이용한 암의 치료
CA3011097C (en) 2016-01-11 2022-12-20 Forty Seven, Inc. Humanized, mouse or chimeric anti-cd47 monoclonal antibodies
AU2017210224B2 (en) 2016-01-21 2024-02-08 The Board Of Trustees Of The Leland Stanford Junior University Treatment of cancer with combinations of immunoregulatory agents
KR20240016445A (ko) * 2016-04-15 2024-02-06 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 암의 치료에서 항-cd47 제제의 치료적으로 효과적인 용량을 결정하고 달성하는 방법
US9957576B2 (en) 2016-04-21 2018-05-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for determining responsiveness to an anti-CD47 agent
US11142548B2 (en) 2016-05-10 2021-10-12 Sorbonne Universite Agents that activate CD47 and their use in the treatment of inflammation
CN106117354B (zh) * 2016-06-24 2020-01-14 安徽未名细胞治疗有限公司 一种全人源抗CD47的全分子IgG抗体及其应用
JP7241677B2 (ja) * 2016-07-19 2023-03-17 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド 抗ｃｄ４７併用療法
WO2018014068A1 (en) * 2016-07-19 2018-01-25 Teva Pharmaceuticals Australia Pty Ltd Attenuated type i ifn cd47 combination therapy
EP3493845A4 (en) 2016-08-03 2020-04-15 The Board of Trustees of the Leland Stanford Junior University INTERRUPTION OF FC RECEPTOR USE ON MACROPHAGES TO IMPROVE THE EFFECTIVENESS OF ANTI-SIRPALPHA ANTIBODY THERAPY
US20200140565A1 (en) 2016-10-20 2020-05-07 I-Mab Novel cd47 monoclonal antibodies and uses thereof
EP3529276A4 (en) 2016-10-21 2020-06-17 Arch Oncology, Inc. CD47 THERAPEUTIC ANTIBODIES
EP3532497B1 (en) 2016-10-26 2024-07-24 The Board of Trustees of the Leland Stanford Junior University Modified immunoglobulin hinge regions to reduce hemagglutination
CA3042581A1 (en) 2016-11-03 2018-05-11 Trillium Therapeutics Inc. Enhancement of cd47 blockade therapy by proteasome inhibitors
EP3538557A4 (en) * 2016-11-08 2020-11-18 Ablexis, LLC ANTI-CD47 ANTIBODY
TW201819413A (zh) * 2016-11-28 2018-06-01 大陸商江蘇恆瑞醫藥股份有限公司 Ｃｄ４７抗體、其抗原結合片段及其醫藥用途
EP3345924A1 (en) 2017-01-10 2018-07-11 Universität Duisburg-Essen Use of cd47 antibodies
KR102607101B1 (ko) * 2017-01-26 2023-11-29 제트엘아이피 홀딩 리미티드 Cd47 항원 결합 유닛 및 그것의 사용
IL301075B2 (en) 2017-01-30 2024-05-01 Univ Leland Stanford Junior A genotoxic matching regimen for stem cell transplantation
CN108424461B (zh) * 2017-02-14 2023-03-31 亘喜生物科技（上海）有限公司 Cd47-car-t细胞
CN110300603B (zh) 2017-02-14 2023-04-14 亘喜生物科技（上海）有限公司 Cd47-car-t细胞
CA3053392A1 (en) 2017-02-28 2018-09-07 The Board Of Trustees Of The Leland Stanford Junior University Antifibrotic activity of cd47 blockade
WO2018165015A1 (en) 2017-03-09 2018-09-13 The Board Of Trustees Of The Leland Stanford Junior University Treatment of pediatric brain tumors with targeting of cd47 pathway
WO2018236904A1 (en) 2017-06-19 2018-12-27 Surface Oncology, Inc. COMBINATION OF ANTI-CD47 ANTIBODIES AND CELL DEATH INDUCING AGENTS, AND USES THEREOF
ES2976558T3 (es) 2017-06-21 2024-08-05 The Board Of Trustees Of The Leland Stanfordjunior Univ Parámetros de dosificación para terapias de direccionamiento de CD47 en neoplasias hematológicas
WO2019014398A1 (en) 2017-07-11 2019-01-17 Actym Therapeutics, Inc. MODIFIED IMMUNOSTIMULATORY BACTERIAL STRAINS AND USES THEREOF
MX2020001309A (es) 2017-08-02 2020-08-20 Phanes Therapeutics Inc Anticuerpos anti-cd47 y sus usos.
WO2019034895A1 (en) 2017-08-18 2019-02-21 Ultrahuman Four Limited LIAISON AGENTS
CN109422811A (zh) * 2017-08-29 2019-03-05 信达生物制药(苏州)有限公司 抗cd47抗体及其用途
EA039662B1 (ru) 2017-10-03 2022-02-24 Закрытое Акционерное Общество "Биокад" Антитела, специфичные к cd47 и pd-l1
EP4194470A1 (en) 2017-10-18 2023-06-14 Forty Seven, Inc. Treatment of ovarian cancer with anti-cd47 and anti-pd-l1
PL4177270T3 (pl) 2017-10-18 2024-11-18 Forty Seven, Inc. Terapia nowotworu złośliwego jajnika w oparciu o środek anty-cd47
AR113862A1 (es) * 2017-12-01 2020-06-17 Seattle Genetics Inc Anticuerpos anti-cd47 y sus usos para tratar cáncer
WO2019129054A1 (zh) 2017-12-27 2019-07-04 信达生物制药(苏州)有限公司 三链抗体、其制备方法及其用途
BR112020014202A2 (pt) 2018-01-12 2020-12-01 Aurigene Discovery Technologies Limited compostos de 1,2,4-oxadiazol como inibidores de vias de sinalização cd47
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
EP3752190B1 (en) 2018-02-12 2022-07-06 Forty Seven, Inc. Anti-cancer regimen using anti-cd47 and anti-cd20 antibodies
CN110144009B (zh) * 2018-02-14 2020-01-21 上海洛启生物医药技术有限公司 Cd47单域抗体及其用途
CN110305212A (zh) 2018-03-27 2019-10-08 信达生物制药(苏州)有限公司 抗cd47抗体及其用途
GB201804860D0 (en) * 2018-03-27 2018-05-09 Ultrahuman Two Ltd CD47 Binding agents
WO2019200357A1 (en) 2018-04-12 2019-10-17 Surface Oncology, Inc. Biomarker for cd47 targeting therapeutics and uses therefor
CN110538321B (zh) * 2018-05-29 2023-03-10 江苏恒瑞医药股份有限公司 一种cd47抗体药物组合物及其用途
CN110577597B (zh) * 2018-06-11 2021-10-22 康诺亚生物医药科技（成都）有限公司 一种阻断CD47和SIRPα相互作用的抗体
EP3808376A4 (en) 2018-06-17 2021-09-01 L&L Biopharma Co., Ltd. CLDN18.2 ANTIBODY, BISPECIFIC ANTIBODY, ADC AND CAR, AND APPLICATIONS THEREOF
WO2020009725A1 (en) * 2018-07-05 2020-01-09 Trican Biotechnology Co., Ltd Human anti-cd47 antibodies and uses thereof
MX2020013068A (es) 2018-07-10 2021-03-02 Univ Kobe Nat Univ Corp Anticuerpo anti proteína reguladora de señales alfa sirpalfana.
CA3176812A1 (en) 2018-07-11 2020-01-16 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
WO2020047161A2 (en) 2018-08-28 2020-03-05 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
KR102587442B1 (ko) * 2018-08-31 2023-10-11 난징 산홈 팔마세우티칼 컴퍼니 리미티드 항-cd47 항체 또는 그 적용
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
AU2019375193A1 (en) 2018-11-08 2021-05-13 Aurigene Oncology Limited Combination of small molecule CD-47 inhibitors with other anti-cancer agents
UA128431C2 (uk) 2018-11-26 2024-07-10 Форті Севен, Інк. ГУМАНІЗОВАНЕ АНТИТІЛО ДО c-Kit
KR20210094609A (ko) 2018-11-28 2021-07-29 포티 세븐, 인코포레이티드 절제 레짐에 대해 저항성인 유전적으로 변형된 hspc
CN113166257B (zh) 2018-12-03 2023-05-30 上海开拓者生物医药有限公司 Cd47抗体及其制备方法和应用
JP2022521624A (ja) * 2019-02-26 2022-04-11 イノベント バイオロジックス （スウツォウ） カンパニー，リミテッド 抗ｃｄ４７抗体を含む製剤、その調製方法および使用
EP3936526A4 (en) 2019-03-06 2023-03-08 Jiangsu Hengrui Pharmaceuticals Co., Ltd. BIFUNCTIONAL FUSION PROTEIN AND PHARMACEUTICAL USE THEREOF
WO2020198353A1 (en) * 2019-03-26 2020-10-01 Forty Seven, Inc. Multispecific agents for treatment of cancer
WO2020206033A1 (en) 2019-04-02 2020-10-08 Kenjockety Biotechnology, Inc. Efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto
CN110003335B (zh) * 2019-04-12 2023-07-04 深圳普瑞金生物药业股份有限公司 Cd47单域抗体、核酸及试剂盒
CA3141130A1 (en) 2019-05-31 2020-12-03 ALX Oncology Inc. Methods of treating cancer with sirp alpha fc fusion in combination with an immune checkpoint inhibitor
TW202112354A (zh) * 2019-06-05 2021-04-01 美商西雅圖遺傳學公司 遮蔽抗體調配物
TW202112801A (zh) 2019-06-05 2021-04-01 美商西雅圖遺傳學公司 純化遮蔽抗體之方法
AU2020315598B2 (en) 2019-07-16 2024-12-12 Gilead Sciences, Inc. HIV vaccines and methods of making and using
US20220288118A1 (en) * 2019-07-31 2022-09-15 Forty Seven, Inc. Depletion regimes for engineered t-cell or nk-cell therapy
JP7808546B2 (ja) 2019-09-03 2026-01-29 中山康方生物医▲藥▼有限公司 抗ｃｄ４７モノクローナル抗体及びその使用
AU2020350205A1 (en) 2019-09-18 2022-05-12 Lamkap Bio Alpha AG Bispecific antibodies against CEACAM5 and CD3
CN112646038B (zh) 2019-10-11 2025-06-03 迈威(上海)生物科技股份有限公司 抗人Trop-2抗体及其应用
PH12022550835A1 (en) 2019-10-18 2023-07-03 Forty Seven Inc Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
NZ786589A (en) 2019-10-31 2025-03-28 Forty Seven Llc Anti-cd47 and anti-cd20 based treatment of blood cancer
WO2021108693A1 (en) 2019-11-27 2021-06-03 ALX Oncology Inc. Combination therapies for treating cancer
GB201918230D0 (en) 2019-12-11 2020-01-22 Prec Therapeutics Ltd Antibodies and their uses
CN115362003B (zh) 2019-12-24 2024-03-22 卡尔那生物科学株式会社 二酰基甘油激酶调节化合物
CN114929749A (zh) 2020-01-09 2022-08-19 信达生物制药(苏州)有限公司 抗cd47抗体和抗cd20抗体的组合在制备用于预防或治疗肿瘤的药物中的应用
US12692311B2 (en) 2020-01-29 2026-07-28 William Robert Arathoon Living Trust Dated August 29, 2016 Anti-MDR1 antibodies and uses thereof
TWI890283B (zh) 2020-02-14 2025-07-11 美商基利科學股份有限公司 結合ccr8之抗體及融合蛋白及其用途
WO2021170772A1 (en) 2020-02-26 2021-09-02 Aprea Therapeutics Ab Combination treatment with a p53 reactivator and an inhibitor of cd47 mediated signaling
WO2021170082A1 (zh) 2020-02-28 2021-09-02 南京圣和药业股份有限公司 抗cd47/抗pd-l1抗体及其应用
US12091681B2 (en) 2020-03-27 2024-09-17 Mendus B.V. Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
CN113461817B (zh) 2020-03-31 2025-04-18 苏州泽璟生物制药股份有限公司 一种抗人cd47抗体及其抗原结合片段、制备方法和应用
US20240294635A1 (en) 2020-04-02 2024-09-05 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Antigen-binding polypeptide binding to cd47, and use thereof
EP4168449A1 (en) 2020-06-22 2023-04-26 MorphoSys AG Anti-tumor combination therapy comprising anti-cd19 antibody and polypeptides blocking the sirpa-cd47 innate immune checkpoint
WO2022003568A1 (en) 2020-06-30 2022-01-06 Dcprime B.V. Use of leukemia-derived cells in ovarian cancer vaccines
CA3200514A1 (en) 2020-11-03 2022-05-12 Rdiscovery, LLC Therapies for treatment of cancer and phagocytosis-deficiency related diseases
WO2022095970A1 (zh) 2020-11-06 2022-05-12 百奥泰生物制药股份有限公司 双特异抗体及其应用
EP4253415A4 (en) 2020-11-12 2024-10-02 Mabwell (Shanghai) Bioscience Co., Ltd. Antibody and preparation method therefor
US12551584B1 (en) 2020-12-07 2026-02-17 Actinium Pharmaceuticals, Inc. Lewis Y radioimmunotherapy for the treatment of cancer
WO2022130016A1 (en) 2020-12-18 2022-06-23 Instil Bio (Uk) Limited Tumor infiltrating lymphocytes and anti-cd47 therapeutics
JP7454044B2 (ja) 2020-12-23 2024-03-21 グアンドン ファポン バイオファーマ インコーポレイテッド Ｃｄ４７を標的とする抗体及びその使用
CN116917322A (zh) 2021-02-19 2023-10-20 沙裴隆有限公司 针对pd-l1及cd47的双特异性单域抗体及其用途
BR112023016713A2 (pt) 2021-02-19 2023-10-31 Seoul Nat Univ R&Db Foundation Anticorpo ou um fragmento de ligação ao antígeno do mesmo, molécula de ácido nucleico, métodos para produzir um anticorpo ou um fragmento de ligação ao antígeno do mesmo e para detectar agrupamento de diferenciação 47 ou determinar uma quantidade de agrupamento de diferenciação 47 em uma amostra, e, uso do anticorpo ou de um fragmento de ligação ao antígeno do mesmo
WO2022190058A1 (en) 2021-03-12 2022-09-15 Dcprime B.V. Methods of vaccination and use of cd47 blockade
WO2022206975A1 (zh) * 2021-04-02 2022-10-06 原启生物科技(上海)有限责任公司 Cldn18.2抗原结合蛋白及其用途
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
JP2024520902A (ja) 2021-05-13 2024-05-27 エーエルエックス オンコロジー インコーポレイテッド がんを治療するための併用療法
EP4353265A4 (en) 2021-06-10 2024-10-02 ONO Pharmaceutical Co., Ltd. METHOD OF TREATING CANCER BY MEANS OF A COMBINATION OF A CD47 INHIBITOR, AN IMMUNE CHECKPOINT INHIBITOR AND STANDARD THERAPY
EP4359413A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CN117355531A (zh) 2021-06-23 2024-01-05 吉利德科学公司 二酰基甘油激酶调节化合物
MX2023014762A (es) 2021-06-23 2024-01-15 Gilead Sciences Inc Compuestos moduladores de diacilglicerol quinasa.
JP7651018B2 (ja) 2021-06-23 2025-03-25 ギリアード サイエンシーズ， インコーポレイテッド ジアシルグリセロールキナーゼ調節化合物
US20240165229A1 (en) 2021-06-29 2024-05-23 Seagen Inc. Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist
CN115702931A (zh) 2021-08-06 2023-02-17 百奥泰生物制药股份有限公司 抗pd-l1/cd47双特异抗体在治疗疾病中的应用
CN115925940B (zh) * 2021-08-24 2026-02-27 上海鑫湾生物科技有限公司 特异性结合cd47的抗体、其重组溶瘤病毒及其用途
AR127270A1 (es) * 2021-10-09 2024-01-03 Hutchmed Ltd Formulación de anticuerpos anti-cd47
CN115991784A (zh) 2021-10-19 2023-04-21 宝船生物医药科技(上海)有限公司 抗cd47-cldn18.2双特异性抗体及其用途
EP4423078A1 (en) 2021-10-28 2024-09-04 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
PE20241186A1 (es) 2021-10-29 2024-06-03 Gilead Sciences Inc Compuestos de cd73
WO2023092089A1 (en) 2021-11-19 2023-05-25 Kist (Korea Institute Of Science And Technology) Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a target cell
CN118488948A (zh) 2021-12-22 2024-08-13 吉利德科学公司 Ikaros锌指家族降解剂及其用途
US20240124412A1 (en) 2021-12-22 2024-04-18 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
EP4458862A4 (en) * 2021-12-27 2026-05-06 Shanghai Sinobay Biotechnology Co Ltd BI-SPECIFIC T-LYMPHOCYTE ACTIVATOR, RECOMINATING ONCOLYTIC VIRUS OF THIS ONE AND ASSOCIATED USE
CA3248911A1 (en) 2022-01-28 2023-08-03 Gilead Sciences, Inc. POLY(ADENOSINE DIPHOSPHATE-RIBOSE) POLYMERASE 7 INHIBITORS
EP4479084A1 (en) 2022-02-14 2024-12-25 Sana Biotechnology, Inc. Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
CN114573710A (zh) * 2022-02-16 2022-06-03 南方医科大学珠江医院 一种靶向抗原同时外泌cd47抗体的免疫细胞及其应用
PL4245756T3 (pl) 2022-03-17 2025-02-17 Gilead Sciences, Inc. Środki degradujące palec cynkowy z rodziny ikaros i ich zastosowania
WO2023183313A1 (en) 2022-03-22 2023-09-28 Sana Biotechnology, Inc. Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods
AU2023240346A1 (en) 2022-03-24 2024-09-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TWI876305B (zh) 2022-04-05 2025-03-11 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
EP4511127A1 (en) 2022-04-21 2025-02-26 Gilead Sciences, Inc. Kras g12d modulating compounds
EP4527853A1 (en) 2022-05-19 2025-03-26 Shaperon Inc. Bispecific humanized single domain antibody to pd-l1 and cd47, and use thereof
WO2024006929A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Cd73 compounds
CA3259040A1 (en) 2022-07-12 2024-01-18 Gilead Sciences, Inc. HIV Immunogenic Polypeptides and Vaccines and Their Uses
US20240091351A1 (en) 2022-09-21 2024-03-21 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY
CN119968212A (zh) * 2022-10-14 2025-05-09 南京传奇生物科技有限公司 靶向cd47的抗体及其用途
EP4638436A1 (en) 2022-12-22 2025-10-29 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2024146553A1 (en) * 2023-01-04 2024-07-11 Wuxi Biologics (Shanghai) Co., Ltd. Antibodies against cd47, method for preparing the same, and use thereof
CN116836290B (zh) * 2023-01-04 2024-10-22 科弈(浙江)药业科技有限公司 针对pd-l1和cd47的双特异性抗体、其制备方法及其用途
WO2024215754A1 (en) 2023-04-11 2024-10-17 Gilead Sciences, Inc. Kras modulating compounds
PE20260121A1 (es) 2023-04-21 2026-01-16 Gilead Sciences Inc Inhibidores de prmt5 y usos de los mismos
JP2026522894A (ja) 2023-06-30 2026-07-09 ギリアード サイエンシーズ， インコーポレイテッド Ｋｒａｓ調節化合物
CN121568935A (zh) 2023-07-26 2026-02-24 吉利德科学公司 Parp7抑制剂
AU2024297978A1 (en) 2023-07-26 2026-02-05 Gilead Sciences, Inc. Parp7 inhibitors
EP4516807A1 (en) 2023-08-28 2025-03-05 Consorcio Centro de Investigación Biomédica en Red Compositions for use in a method of providing improved hematopoietic stem cell engraftment
EP4774280A1 (en) 2023-09-08 2026-07-15 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2025096589A1 (en) 2023-11-03 2025-05-08 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025245003A1 (en) 2024-05-21 2025-11-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20260098049A1 (en) 2024-08-12 2026-04-09 Gilead Sciences, Inc. Kras modulating compounds
US20260130893A1 (en) 2024-10-21 2026-05-14 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2026136515A1 (en) 2024-12-19 2026-06-25 Gilead Sciences, Inc. Parp7 inhibitors

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1549776A (en) 1975-08-07 1979-08-08 Girling Ltd Double acting valved pistons
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
JPS5547656U (pl) 1978-09-22 1980-03-28
US4867973A (en) 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5057604A (en) * 1988-08-03 1991-10-15 Washington University Novel monoclonal antibodies
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JPH0747841B2 (ja) 1991-02-15 1995-05-24 ゼニヤ海洋サービス株式会社 浮体の自沈装置
PT528767E (pt) * 1991-08-21 2000-06-30 Novartis Ag Derivados de anticorpos
US5792852A (en) * 1992-11-16 1998-08-11 Cancer Research Fund Of Contra Costa Polynucleotides encoding modified antibodies with human milk fat globule specificity
US6986890B1 (en) * 1996-11-21 2006-01-17 Kyowa Hakko Kogyo Co., Ltd. Anti-human VEGF receptor Flt-1 monoclonal antibody
US6908763B1 (en) 1997-08-22 2005-06-21 The Board Of Trustees Of The Leland Stanford Junior University Mammalian common lymphoid progenitor cell
US6051228A (en) * 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
US6491917B1 (en) 1998-07-31 2002-12-10 Stemcell Technologies Inc. Antibody composition for debulking blood and bone marrow samples from CML patients
ATE413466T1 (de) * 1998-09-02 2008-11-15 Diadexus Inc Verfahren zur diagnose, bewertung sowie bilddarstellung verschiedener krebserkrankungen
AU1208200A (en) * 1998-10-15 2000-05-01 Genetics Institute Inc. Secreted expressed sequence tags (sests)
US20030096976A1 (en) * 1998-11-17 2003-05-22 Hong Hyo Jeong Humanized antibodies LB-00503 and LB-00506 specific for human 4-1BB and pharmaceutical compositions comprising said humanized antibodies
AU2940900A (en) * 1999-03-10 2000-09-28 Chugai Seiyaku Kabushiki Kaisha Single-stranded fv inducing apoptosis
US20090087878A9 (en) * 1999-05-06 2009-04-02 La Rosa Thomas J Nucleic acid molecules associated with plants
DE60036470T2 (de) 1999-06-29 2008-06-19 The Board Of Trustees Of The Leland Stanford Junior University, Palo Alto Untereinheiten von myeloid-progenitorzellen von säugern
ATE510855T1 (de) 2000-03-06 2011-06-15 Univ Kentucky Res Found Verwendung eines antikörpers oder eines immunotoxins, der bzw. das selektiv an cd123 bindet zur beeinträchtigung hämatologischer krebs-vorläuferzellen
US6838250B2 (en) * 2000-03-31 2005-01-04 Ortho-Clinical Diagnostics, Inc. Immunoassay for C-reactive protein
CN1308447C (zh) * 2000-10-20 2007-04-04 中外制药株式会社 低分子化的激动剂抗体
US7408041B2 (en) * 2000-12-08 2008-08-05 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US20050118164A1 (en) 2001-03-09 2005-06-02 William Herman Targeted ligands
US20050142539A1 (en) 2002-01-14 2005-06-30 William Herman Targeted ligands
JP3632668B2 (ja) 2002-02-18 2005-03-23 ミノルタ株式会社 デジタルカメラ
CA2480059C (en) * 2002-03-22 2015-11-24 Amrad Operations Pty. Ltd. Monoclonal antibody against interleukin-13 receptor alpha 1 (il-13r.alpha.1)
AR045563A1 (es) * 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
JP4637749B2 (ja) 2003-11-11 2011-02-23 中外製薬株式会社 ヒト化抗ｃｄ４７抗体
US7622112B2 (en) * 2003-12-05 2009-11-24 Jody Berry Anti-SARS monoclonal antibodies
US20070287163A1 (en) 2004-05-17 2007-12-13 Crucell Holland B.V. Methods for Diagnosis of Acute Myeloid Leukemia
EP1853630A1 (en) * 2004-10-22 2007-11-14 Applied Molecular Evolution Inc. Methods of optimizing antibody variable region binding affinity
EP2172487A1 (en) 2005-04-22 2010-04-07 Morphotek Inc. Antibodies with Immune Effector Activity that Internalize in Folate Receptor Alpha-Positive Cells
CA2613818C (en) * 2005-06-30 2013-08-27 Centocor, Inc. Anti-il-23 antibodies, compositions, methods and uses
US7888486B2 (en) * 2005-08-19 2011-02-15 Wyeth Llc Antagonist antibodies against GDF-8
ME02705B (me) * 2005-08-31 2017-10-20 Merck Sharp & Dohme Inženjerisana anti-il-23 antitela
WO2007033221A2 (en) 2005-09-13 2007-03-22 The General Hospital Corporation Methods and compositions for inhibition of immune responses
KR101336106B1 (ko) 2005-09-16 2013-12-05 얀센 파마슈티카 엔.브이. 히스타민 ｈ3 수용체의 조절제로서 사이클로프로필 아민
US20090191202A1 (en) * 2005-09-29 2009-07-30 Jamieson Catriona Helen M Methods for manipulating phagocytosis mediated by CD47
US7514229B2 (en) 2005-09-29 2009-04-07 The Board Of Trustees Of The Leland Stanford Junior University Methods for diagnosing and evaluating treatment of blood disorders
WO2007064919A2 (en) * 2005-12-02 2007-06-07 Genentech, Inc. Binding polypeptides with restricted diversity sequences
WO2007133811A2 (en) * 2006-05-15 2007-11-22 Viral Logic Systems Technology Corp. Cd47 related compositions and methods for treating immunological diseases and disorders
CA2657621A1 (en) * 2006-07-14 2008-01-17 Aviva Biosciences Corporation Methods and compositions for detecting rare cells from a biological sample
WO2008035894A1 (en) * 2006-09-19 2008-03-27 Sungkyunkwan University Foundation For Corporate Collaboration Antiviral agent against animal viruses
WO2008073316A2 (en) 2006-12-07 2008-06-19 The Board Of Trustees Of The Leland Stanford Junior University Identification and isolation of acute myeloid leukemia stem cells
US8026345B2 (en) * 2007-01-08 2011-09-27 Hoffmann-La Roche Inc. Characterization and identification of unique human adiponectin isoforms and antibodies
JP4453724B2 (ja) 2007-06-29 2010-04-21 株式会社デンソー 車両用冷凍サイクル装置
AU2008282863A1 (en) * 2007-07-31 2009-02-05 Merck Sharp & Dohme Corp. IGF-1R specific antibodies useful in the detection and diagnosis of cellular proliferative disorders
TW200944231A (en) * 2007-11-30 2009-11-01 Glaxo Group Ltd Antigen-binding constructs
PT3056515T (pt) 2008-01-15 2019-07-19 Univ Leland Stanford Junior Métodos para manipulação da fagocitose mediada por cd47
WO2010017332A2 (en) * 2008-08-07 2010-02-11 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services Radioprotectants targeting thrombospondin-1 and cd47
EP2497025A1 (en) 2009-11-04 2012-09-12 ST-Ericsson (France) SAS Dynamic management of random access memory
AU2011252851B2 (en) * 2010-05-14 2016-10-06 The Board Of Trustees Of The Leland Stanford Junior University Humanized and chimeric monoclonal antibodies to CD47

Also Published As

Publication number Publication date
US9382320B2 (en) 2016-07-05
US11807684B2 (en) 2023-11-07
JP2019216719A (ja) 2019-12-26
PT3789038T (pt) 2023-01-16
JP2013534409A (ja) 2013-09-05
JP7199494B2 (ja) 2023-01-05
EP2569013A4 (en) 2015-04-08
EP4349868A3 (en) 2024-08-28
HRP20221260T1 (hr) 2023-03-03
PT2569013T (pt) 2017-02-08
JP6964631B2 (ja) 2021-11-10
AU2023202660A1 (en) 2023-05-18
AU2011252851A1 (en) 2012-11-22
JP7412521B2 (ja) 2024-01-12
US9017675B2 (en) 2015-04-28
CA2797720A1 (en) 2011-11-17
AU2016273893A1 (en) 2017-01-12
AU2018204448A1 (en) 2018-07-12
HUE031778T2 (en) 2017-07-28
US20240084006A1 (en) 2024-03-14
EP2569013B1 (en) 2016-11-23
JP2023051986A (ja) 2023-04-11
HUE060541T2 (hu) 2023-03-28
EP3789038A1 (en) 2021-03-10
CA3138956A1 (en) 2011-11-17
AU2023202660B2 (en) 2026-07-09
JP6943549B2 (ja) 2021-10-06
EP3789038B1 (en) 2022-10-05
US20210246206A1 (en) 2021-08-12
WO2011143624A2 (en) 2011-11-17
US20150183874A1 (en) 2015-07-02
WO2011143624A3 (en) 2012-01-19
DK3789038T3 (da) 2022-10-17
JP6166177B2 (ja) 2017-07-19
EP4349868A2 (en) 2024-04-10
LT3789038T (lt) 2022-12-12
JP7763230B2 (ja) 2025-10-31
AU2020203132A1 (en) 2020-06-04
AU2011252851B2 (en) 2016-10-06
US20210087269A1 (en) 2021-03-25
DK2569013T3 (da) 2017-02-13
JP2024050548A (ja) 2024-04-10
US20130142786A1 (en) 2013-06-06
ES2937174T3 (es) 2023-03-24
JP2022031635A (ja) 2022-02-22
AU2020203132B2 (en) 2023-02-02
US20160304609A1 (en) 2016-10-20
US11014985B2 (en) 2021-05-25
HRP20170254T1 (hr) 2017-04-21
EP2569013A2 (en) 2013-03-20
JP2017039709A (ja) 2017-02-23
EP3181149A1 (en) 2017-06-21
ES2616010T3 (es) 2017-06-09
CA2797720C (en) 2021-11-16

Similar Documents

Publication Publication Date Title
HUE060541T2 (hu) Humanizált és kiméra monoklonális CD47 elleni ellenanyagok
ES3065861T3 (en) Interleukin-31 monoclonal antibody
LTPA2021001I1 (lt) Anti-PD-L1 antikūnai ir jų panaudojimas
DK2521736T3 (da) Humaniserede antistoffer
HRP20181360T1 (hr) Anti-cd28 humanizirana protutijela
IL254004A0 (en) Monoclonal antibodies to progastrin and their uses
IL221408B (en) Monoclonal antibodies against c-met
SMT201700083B (it) Anticorpi monoclonali
BR112013032552A2 (pt) variantes de anticorpos monoclonais humanizados imunomoduladores
LT2975051T (lt) Lengvai išskiriami bispecifiniai antikūnai su natyvios formos imunoglobulinu
BR112013022797A2 (pt) anticorpos anti-ctla4 humanizados
SMT201400184B (it) Anticorpi monoclonali che legano b7h6 e loro usi
BRPI0907532A2 (pt) Anticorpos anti-c5ar humanizados
EP2542262A4 (en) Monoclonal antibodies directed to cd20
BR112013002297A2 (pt) anticorpos humanizados seguros e funcionais
HRP20180728T1 (hr) Humanizirana protutijela koja prepoznaju alfa-sinuklein
CR20170001A (es) Anticuerpos anti factor d humanizados
BRPI0908508A2 (pt) anticorpo monoclonal nkg2a anti-humano humanizado
DK3351255T3 (da) Modificerede anti-cd4-antistoffer
HUE036157T2 (hu) Humanizált IL-25 ellenanyagok
EP2545075A4 (en) HUMANIZED AND CHIMERIC ANTIBODIES AGAINST PROPERDIN
PT2407537E (pt) Anticorpo pcrv humanizado com atividade anti-pseudomonal